Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cost-effective conventional endpoint PCR assay for HLA-B*13:01 genotyping to guide personalized dapsone therapy in leprosy in low-resource settings.

Personalized medicine - 1 Aug 2026

Rana Divya Rsjb, Koju Kishor, Shakya Jivan, Manandhar Sarita, Singh Anjana, Shah Mahesh, Hagge Deanna A, Joshi Jarina

Abstract excerpt

BACKGROUND: Dapsone is a drug used to treat leprosy. Dapsone causes a highly morbid and potentially fatal severe drug hypersensitivity reaction (DHS) in 1-3% of leprosy cases. The allele HLA-B*13:01 is a known genetic risk factor for DHS. However, resource-intensive genotyping methods preclude its testing in resource-limited settings. This study aimed to develop an endpoint PCR assay to detect the presence of...

Read the complete abstract on PubMed

Topics

Humans
Dapsone
Leprosy
Polymerase Chain Reaction
Genotype
Alleles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Drug Hypersensitivity

Cost-Benefit Analysis

Female

HLA-B13 Antigen

Genotyping Techniques

Male

Sensitivity and Specificity

Leprostatic Agents

HLA-B Antigens

Adult

Source

Identifiers

PMID: 42669080
DOI: 10.1080/17410541.2026.2724106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cost-effective conventional endpoint PCR assay for HLA-B*13:01 genotyping to guide personalized dapsone therapy in leprosy in low-resource settings.PMID 42669080Read ↗

HLA-B*13:01 and the dapsone hypersensitivity syndrome.Semantic proximity Read ↗

Validation Study of HLA-B*13:01 as a Biomarker of Dapsone Hypersensitivity Syndrome in Leprosy Patients in IndonesiaSemantic proximity Read ↗

Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.Semantic proximity Read ↗

Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01.Semantic proximity Read ↗

A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.Semantic proximity Read ↗

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients.Semantic proximity Read ↗

A low-cost, sensitive and specific PCR-based tool for rapid clinical detection of HLA-B*35 alleles associated with delayed drug hypersensitivity reactions.Semantic proximity Read ↗

Development of an ARMS multiplex real-time PCR assay for the detection of HLA-B*13:01 genotype by detecting highly specific SNPs.Semantic proximity Read ↗

Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in ThailandSemantic proximity Read ↗

Ultrarapid and high-resolution HLA class I typing using transposase-based nanopore sequencing applied in pharmacogenetic testingSemantic proximity Read ↗

Prevalence of HLA-B*57:01 and complete linkage disequilibrium with HCP5 rs2395029: Prevalence and DetectionSemantic proximity Read ↗

Development of multiplex pyrosequencing for HLA-B*57:01 screening using single nucleotide polymorphism haplotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.